# Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

> **NCT00472966** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 20 (actual)

## Conditions studied

- Melasma

## Interventions

- **DRUG:** Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels

## Key facts

- **NCT ID:** NCT00472966
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472966, "Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00472966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*